Join to View Full Profile
44 Binney Streetd1b30Danafarber Cancer InstituteBoston, MA 02115
Phone+1 617-632-5946
Fax+1 617-632-5168
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Corey Cutler, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Vermont, and Florida. He is an Associate Professor at Harvard Medical.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
McGill University Faculty of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026
VT State Medical License 2023 - 2026
American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 1 citationsDeficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD.Michael C Zaiken, Sujeong Jin, Cameron S McDonald-Hyman, Christina R Hartigan, Peter T Sage
Blood. 2025-06-12 - 4 citationsClinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT.Carmelo Gurnari, Marie Robin, Lionel Adès, Mahmoud Aljurf, Antonio Almeida
Blood. 2025-05-01 - 4 citationsIbrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.Joseph Pidala, Jongphil Kim, Denise Kalos, Corey Cutler, Zachariah DeFilipp
Blood Advances. 2025-03-11
Press Mentions
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025- FDA Approves Treatment for Chronic Graft Versus Host DiseaseSeptember 6th, 2024
- Notice of Compliance Issued Regarding Rezurock(TM) (Belumosudil Tablets)March 21st, 2023
- Join now to see all
Grant Support
- Mechanisms and Therapy of Chronic Graft-vs.-Host DiseaseDANA-FARBER CANCER INST2022–2027
